Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This phase III trial compares the addition of apalutamide, with or without targeted radiation
therapy, to standard of care treatment versus standard of care treatment alone in patients
with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific
antigen [PSA] after treatment with surgery or radiation). Diagnostic procedures, such as
positron emission tomography/computed tomography (PET/CT), may help doctors look for cancer
that has spread to the pelvis. Androgens can cause the growth of prostate cancer cells.
Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor
cells. Targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors
that have spread. This trial may help doctors determine if using PET/CT results to deliver
more tailored treatment (i.e., adding apalutamide, with or without targeted radiation
therapy, to standard of care treatment) works better than standard of care treatment alone in
patients with biochemical recurrence of prostate cancer.